Amarin Corp Ads (AMRN) 2.92 $AMRN
Amarin (AMRN) Ends Patient Randomization in Vascepa Study
Zacks Equity Research - Zacks Investment Research - Thu Sep 01, 9:20AM CDT
Amarin (AMRN) announced that it has finished randomizing patients in the phase III REDUCE-IT study on Vascepa (icosapent ethyl).
ANIP: 59.86 (-1.56), AMRN: 2.92 (+0.13), ANIK: 47.89 (-0.05), PCRX: 39.04 (-1.33)
Is Amarin Corporation Stock a Solid Choice Right Now?
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 9:11AM CDT
Amarin Corporation (AMRN) is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
AMRN: 2.92 (+0.13)
Amarin Randomizes Final Patient into REDUCE-IT Cardiovascular Outcomes Study of Vascepa
GlobeNewswire - Wed Aug 31, 6:30AM CDT
Amarin Corporation plc (NASDAQ:AMRN) announced that randomization of patients into the REDUCE-IT cardiovascular outcomes study has been completed with 8,175 individual patients randomized, in accordance with the study protocol, on a 1:1 basis between Vascepa (icosapent ethyl) and placebo, slightly exceeding the 8,000 patients targeted for the trial.
AMRN: 2.92 (+0.13)
Amarin Announces Mandatory Exchange of Exchangeable Senior Notes Issued in May 2014 and November 2015
GlobeNewswire - Fri Aug 26, 3:19PM CDT
Amarin Corporation plc (NASDAQ:AMRN) ("Amarin"
, announced today that its wholly owned subsidiary, Corsicanto Limited, a private limited company incorporated under the laws of Ireland (the "Issuer", provided notice that the Issuer has exercised its option to mandatorily exchange all $118.734 million in aggregate principal amount of its 3.50% May 2014 Exchangeable Senior Notes due 2032 (the "2014 Notes" into American Depositary Shares ("ADSs" of Amarin, with each ADS representing one ordinary share of Amarin. As a result, Amarin will issue 384.6154 ADSs per $1,000 principal amount of 2014 Notes, subject to certain adjustments as provided in the Indenture, dated May 20, 2014 by and among the Issuer, Amarin, and Wilmington Trust, National Association, as trustee (the "Indenture" governing the 2014 Notes.
AMRN: 2.92 (+0.13)
Drug Makers Stocks Under Scanner -- Amarin, Depomed, United Therapeutics, and Sucampo Pharma
PR Newswire - Tue Aug 16, 6:40AM CDT
In today's pre-market research, Stock-Callers.com follows four Drug Manufacturing equities, namely, Amarin Corp. PLC (NASDAQ: AMRN), Depomed Inc. (NASDAQ: DEPO), United Therapeutics Corp. (NASDAQ: UTHR), and Sucampo Pharmaceuticals Inc. (NASDAQ: SCMP). Global prescription drug sales are expected to increase 3% this year despite drug-price debates and cost-control pressures. You can access of our complimentary research reports on these stocks now at:
UTHR: 122.91 (-0.30), AMRN: 2.92 (+0.13), SCMP: 11.10 (unch), DEPO: 20.93 (+0.33)
Amarin Announces Underwriters' Exercise of Option to Purchase Additional American Depositary Shares
GlobeNewswire - Mon Aug 15, 6:30AM CDT
Amarin Corporation plc (NASDAQ:AMRN) today announced that, in connection with its previously announced underwritten public offering of American Depositary Shares ("ADSs", the underwriters of the offering have exercised in full their option to purchase up to an aggregate of 3,165,000 additional ADSs. The exercise of this option increases the size of the offering to an aggregate of 24,265,000 ADSs at a price to the public of $2.85 per ADS. The aggregate net proceeds to the company from this offering are expected to be approximately $64.6 million, after deducting underwriting discounts and commissions and other estimated offering expenses. The offering, including the purchase of the additional ADSs, is expected to close on or about August 16, 2016, subject to customary closing conditions.
AMRN: 2.92 (+0.13)
Amarin Prices Public Offering of American Depositary Shares
GlobeNewswire - Thu Aug 11, 8:20AM CDT
Amarin Corporation plc (NASDAQ:AMRN) today announced the pricing of an underwritten public offering of 21,100,000 American Depositary Shares ("ADSs" at a price to the public of $2.85 per ADS. The net proceeds to the company from this offering are expected to be approximately $56.1 million, after deducting underwriting discounts and commissions and other estimated offering expenses. The offering is expected to close on or about August 16, 2016, subject to customary closing conditions.
AMRN: 2.92 (+0.13)
Amarin Announces Proposed Public Offering of American Depositary Shares
GlobeNewswire - Wed Aug 10, 3:10PM CDT
Amarin Corporation plc (NASDAQ:AMRN) today announced that it has commenced an underwritten public offering of its American Depositary pursuant to a shelf registration. All of the shares in the proposed offering are to be sold by Amarin. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.
AMRN: 2.92 (+0.13)
Amarin Reports Second Quarter 2016 Financial Results and Provides Update on Operations
Marketwire Canada - Thu Aug 04, 5:56AM CDT
Second Quarter Net Product Revenue Up 85% vs. Prior Year Period; Increasing Guidance on Full Year Net Product Revenue to $112-$125 Million; Management to Host Conference Call at 7:30 a.m. ET Today
AMRN: 2.92 (+0.13)
Amarin and FDA Reaffirm Concurrence on REDUCE-IT Through Special Protocol Assessment Agreement Amendment
Marketwired - Thu Aug 04, 4:45AM CDT
Primary Endpoint and Overall Study Timing and Size Unchanged; Statistical Analysis Plan Finalized; Second Interim Efficacy Analysis and Additional Pre-Specified Endpoints Added
AMRN: 2.92 (+0.13)
Investor Calendar Invites You to the Amarin Second Quarter 2016 Earnings Conference Call and Webcast Live on Thursday, August 4, 2016
ACCESSWIRE - Wed Aug 03, 3:16PM CDT
BEDMINSTER, NJ and DUBLIN, IRELAND / ACCESSWIRE / August 3, 2016 / Amarin Corporation plc (NASDAQ: AMRN) will host a conference call and live webcast to discuss the results of the second quarter 2016, to be held Thursday, August 4, 2016 at 7:30 AM Eastern Time.
AMRN: 2.92 (+0.13)
Amarin to Report Second Quarter 2016 Results and Host Conference Call at 7:30 A.M. ET on August 4, 2016
Marketwire Canada - Thu Jul 28, 6:00AM CDT
BEDMINSTER, NJ and DUBLIN, IRELAND--(Marketwired - July 28, 2016) - Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to discuss the company's second quarter 2016 financial results and provide an operational update on Thursday, August 4, at 7:30 a.m. ET. The conference call will follow the anticipated release of the company's financial results earlier that day.
AMRN: 2.92 (+0.13)
Featured Research Report on Drug Manufacturers Stocks
ACCESSWIRE - Tue Jun 14, 8:15AM CDT
LONDON, UK / ACCESSWIRE / June 14, 2016 / ActiveWallSt.com announces the list of stocks for today's research coverage. Pre-market the Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on the Drug Manufacturers-Other industry. Companies recently under review include Ionis Pharma, Depomed, Amarin, and United Therapeutics. Register with us now for your free membership and see our complete reports on these equities at:
UTHR: 122.91 (-0.30), AMRN: 2.92 (+0.13), DEPO: 20.93 (+0.33), IONS: 29.46 (-0.58)
Vascepa(R) (Icosapent Ethyl) Showed Significant Reductions in Potentially Atherogenic Lipid Parameters in Statin-Treated Patients With Type 2 Diabetes and Persistent High Triglycerides
Marketwired - Sat Jun 11, 10:00AM CDT
BEDMINSTER, NJ and DUBLIN, IRELAND--(Marketwired - June 11, 2016) - Amarin Corporation plc (NASDAQ: AMRN) today announced additional data on Vascepa (icosapent ethyl) presented at the annual meeting of the American Diabetes Association (ADA) supporting its efficacy in reducing concentrations of potentially atherogenic lipoproteins (lipoproteins that could promote fat deposits in arteries) in patients with Type 2 diabetes and persistent high triglyceride (TG) levels despite statin therapy.
AMRN: 2.92 (+0.13)
Vascepa(R) (Icosapent Ethyl) Data to Be Presented at American Diabetes Association's 76th Scientific Sessions
Marketwire Canada - Mon Jun 06, 6:30AM CDT
BEDMINSTER, NJ AND DUBLIN, IRELAND--(Marketwired - June 06, 2016) - Amarin Corporation plc (NASDAQ: AMRN) today announced that new data related to Vascepa® (icosapent ethyl) will be presented at the upcoming American Diabetes Association (ADA) 76th Scientific Sessions in New Orleans (June 10-14) and published as an abstract in the Diabetes® Abstract Book.
AMRN: 2.92 (+0.13)
Amarin (AMRN) Ends Patient Randomization in Vascepa Study
Zacks Equity Research - Zacks Investment Research - Thu Sep 01, 9:20AM CDT
Amarin (AMRN) announced that it has finished randomizing patients in the phase III REDUCE-IT study on Vascepa (icosapent ethyl).
ANIP: 59.86 (-1.56), AMRN: 2.92 (+0.13), ANIK: 47.89 (-0.05), PCRX: 39.04 (-1.33)
Is Amarin Corporation Stock a Solid Choice Right Now?
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 9:11AM CDT
Amarin Corporation (AMRN) is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
AMRN: 2.92 (+0.13)
Amarin Randomizes Final Patient into REDUCE-IT Cardiovascular Outcomes Study of Vascepa
GlobeNewswire - Wed Aug 31, 6:30AM CDT
Amarin Corporation plc (NASDAQ:AMRN) announced that randomization of patients into the REDUCE-IT cardiovascular outcomes study has been completed with 8,175 individual patients randomized, in accordance with the study protocol, on a 1:1 basis between Vascepa (icosapent ethyl) and placebo, slightly exceeding the 8,000 patients targeted for the trial.
AMRN: 2.92 (+0.13)
Amarin Announces Mandatory Exchange of Exchangeable Senior Notes Issued in May 2014 and November 2015
GlobeNewswire - Fri Aug 26, 3:19PM CDT
Amarin Corporation plc (NASDAQ:AMRN) ("Amarin"
, announced today that its wholly owned subsidiary, Corsicanto Limited, a private limited company incorporated under the laws of Ireland (the "Issuer", provided notice that the Issuer has exercised its option to mandatorily exchange all $118.734 million in aggregate principal amount of its 3.50% May 2014 Exchangeable Senior Notes due 2032 (the "2014 Notes" into American Depositary Shares ("ADSs" of Amarin, with each ADS representing one ordinary share of Amarin. As a result, Amarin will issue 384.6154 ADSs per $1,000 principal amount of 2014 Notes, subject to certain adjustments as provided in the Indenture, dated May 20, 2014 by and among the Issuer, Amarin, and Wilmington Trust, National Association, as trustee (the "Indenture" governing the 2014 Notes. AMRN: 2.92 (+0.13)
Drug Makers Stocks Under Scanner -- Amarin, Depomed, United Therapeutics, and Sucampo Pharma
PR Newswire - Tue Aug 16, 6:40AM CDT
In today's pre-market research, Stock-Callers.com follows four Drug Manufacturing equities, namely, Amarin Corp. PLC (NASDAQ: AMRN), Depomed Inc. (NASDAQ: DEPO), United Therapeutics Corp. (NASDAQ: UTHR), and Sucampo Pharmaceuticals Inc. (NASDAQ: SCMP). Global prescription drug sales are expected to increase 3% this year despite drug-price debates and cost-control pressures. You can access of our complimentary research reports on these stocks now at:
UTHR: 122.91 (-0.30), AMRN: 2.92 (+0.13), SCMP: 11.10 (unch), DEPO: 20.93 (+0.33)
Amarin Announces Underwriters' Exercise of Option to Purchase Additional American Depositary Shares
GlobeNewswire - Mon Aug 15, 6:30AM CDT
Amarin Corporation plc (NASDAQ:AMRN) today announced that, in connection with its previously announced underwritten public offering of American Depositary Shares ("ADSs"
, the underwriters of the offering have exercised in full their option to purchase up to an aggregate of 3,165,000 additional ADSs. The exercise of this option increases the size of the offering to an aggregate of 24,265,000 ADSs at a price to the public of $2.85 per ADS. The aggregate net proceeds to the company from this offering are expected to be approximately $64.6 million, after deducting underwriting discounts and commissions and other estimated offering expenses. The offering, including the purchase of the additional ADSs, is expected to close on or about August 16, 2016, subject to customary closing conditions. AMRN: 2.92 (+0.13)
Amarin Prices Public Offering of American Depositary Shares
GlobeNewswire - Thu Aug 11, 8:20AM CDT
Amarin Corporation plc (NASDAQ:AMRN) today announced the pricing of an underwritten public offering of 21,100,000 American Depositary Shares ("ADSs"
at a price to the public of $2.85 per ADS. The net proceeds to the company from this offering are expected to be approximately $56.1 million, after deducting underwriting discounts and commissions and other estimated offering expenses. The offering is expected to close on or about August 16, 2016, subject to customary closing conditions. AMRN: 2.92 (+0.13)
Amarin Announces Proposed Public Offering of American Depositary Shares
GlobeNewswire - Wed Aug 10, 3:10PM CDT
Amarin Corporation plc (NASDAQ:AMRN) today announced that it has commenced an underwritten public offering of its American Depositary pursuant to a shelf registration. All of the shares in the proposed offering are to be sold by Amarin. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.
AMRN: 2.92 (+0.13)
Amarin Reports Second Quarter 2016 Financial Results and Provides Update on Operations
Marketwire Canada - Thu Aug 04, 5:56AM CDT
Second Quarter Net Product Revenue Up 85% vs. Prior Year Period; Increasing Guidance on Full Year Net Product Revenue to $112-$125 Million; Management to Host Conference Call at 7:30 a.m. ET Today
AMRN: 2.92 (+0.13)
Amarin and FDA Reaffirm Concurrence on REDUCE-IT Through Special Protocol Assessment Agreement Amendment
Marketwired - Thu Aug 04, 4:45AM CDT
Primary Endpoint and Overall Study Timing and Size Unchanged; Statistical Analysis Plan Finalized; Second Interim Efficacy Analysis and Additional Pre-Specified Endpoints Added
AMRN: 2.92 (+0.13)
Investor Calendar Invites You to the Amarin Second Quarter 2016 Earnings Conference Call and Webcast Live on Thursday, August 4, 2016
ACCESSWIRE - Wed Aug 03, 3:16PM CDT
BEDMINSTER, NJ and DUBLIN, IRELAND / ACCESSWIRE / August 3, 2016 / Amarin Corporation plc (NASDAQ: AMRN) will host a conference call and live webcast to discuss the results of the second quarter 2016, to be held Thursday, August 4, 2016 at 7:30 AM Eastern Time.
AMRN: 2.92 (+0.13)
Amarin to Report Second Quarter 2016 Results and Host Conference Call at 7:30 A.M. ET on August 4, 2016
Marketwire Canada - Thu Jul 28, 6:00AM CDT
BEDMINSTER, NJ and DUBLIN, IRELAND--(Marketwired - July 28, 2016) - Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to discuss the company's second quarter 2016 financial results and provide an operational update on Thursday, August 4, at 7:30 a.m. ET. The conference call will follow the anticipated release of the company's financial results earlier that day.
AMRN: 2.92 (+0.13)
Featured Research Report on Drug Manufacturers Stocks
ACCESSWIRE - Tue Jun 14, 8:15AM CDT
LONDON, UK / ACCESSWIRE / June 14, 2016 / ActiveWallSt.com announces the list of stocks for today's research coverage. Pre-market the Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on the Drug Manufacturers-Other industry. Companies recently under review include Ionis Pharma, Depomed, Amarin, and United Therapeutics. Register with us now for your free membership and see our complete reports on these equities at:
UTHR: 122.91 (-0.30), AMRN: 2.92 (+0.13), DEPO: 20.93 (+0.33), IONS: 29.46 (-0.58)
Vascepa(R) (Icosapent Ethyl) Showed Significant Reductions in Potentially Atherogenic Lipid Parameters in Statin-Treated Patients With Type 2 Diabetes and Persistent High Triglycerides
Marketwired - Sat Jun 11, 10:00AM CDT
BEDMINSTER, NJ and DUBLIN, IRELAND--(Marketwired - June 11, 2016) - Amarin Corporation plc (NASDAQ: AMRN) today announced additional data on Vascepa (icosapent ethyl) presented at the annual meeting of the American Diabetes Association (ADA) supporting its efficacy in reducing concentrations of potentially atherogenic lipoproteins (lipoproteins that could promote fat deposits in arteries) in patients with Type 2 diabetes and persistent high triglyceride (TG) levels despite statin therapy.
AMRN: 2.92 (+0.13)
Vascepa(R) (Icosapent Ethyl) Data to Be Presented at American Diabetes Association's 76th Scientific Sessions
Marketwire Canada - Mon Jun 06, 6:30AM CDT
BEDMINSTER, NJ AND DUBLIN, IRELAND--(Marketwired - June 06, 2016) - Amarin Corporation plc (NASDAQ: AMRN) today announced that new data related to Vascepa® (icosapent ethyl) will be presented at the upcoming American Diabetes Association (ADA) 76th Scientific Sessions in New Orleans (June 10-14) and published as an abstract in the Diabetes® Abstract Book.
AMRN: 2.92 (+0.13)
